Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Lung Cancer AJCC v8: early-phase trial registry
37 of 82 indexed Stage IV Lung Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #170 of 28,707 conditions by registered trial count.
82 US clinical trials · 37 currently recruiting · #170 of 28,707 conditions by registered trial count
Stage IV Lung Cancer AJCC v8: 82 US clinical trials tracked, 37 recruiting.
Stage IV Lung Cancer AJCC v8 is the subject of 82 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 59 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 16 of these trials.
Enrollment posture brief
Registry condition stage-iv-lung-cancer-ajcc-v8
OPEN 37 | RECR 45% | LATE 8 | EARLY 59 | RANK #170 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Diabetic Foot (45% recruiting · 31 trials)
Stage IV Lung Cancer AJCC v8 lists 37 open slots (45% of 82 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IV Lung Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IV Lung Cancer AJCC v8 is recruiting above its size-band peers.
37 of 82 indexed trials (45.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IV Lung Cancer AJCC v8 research.
National Cancer Institute (NCI) accounts for 16 of 82 trials (19.5%). 22 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IV Lung Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 37 among the 82 trials that report a genuine target (sentinel values excluded). 62 of those (75.6%) plan for fewer than 100 participants.
-
Stage IV Lung Cancer AJCC v8 research is mostly interventional.
77 interventional and 5 observational studies make up this index (93.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
82 total, page 1 of 2
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
University of Rochester
NCT06073431
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Mayo Clinic
NCT06075524
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT06616584
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
National Cancer Institute (NCI)
NCT06096844
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
National Cancer Institute (NCI)
NCT04181060
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
NCT06500455
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NRG Oncology
NCT04804644
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NRG Oncology
NCT06500481
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
Mayo Clinic
NCT06122064
Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer
M.D. Anderson Cancer Center
NCT06743308
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
University of Washington
NCT04151940
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Emory University
NCT04762199
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT05642572
Insomnia in Patients With Metastatic Lung Cancer
Mayo Clinic
NCT06472804
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Dwight Owen
NCT04919382
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT06031688
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
NCT06495125
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT06287775
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
National Cancer Institute (NCI)
NCT07012031
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
City of Hope Medical Center
NCT06910761
Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer
Rutgers, The State University of New Jersey
NCT04751747
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
City of Hope Medical Center
NCT06014827
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Dwight Owen
NCT05234307
Gilteritinib for the Treatment of ALK NSCLC
University of Michigan Rogel Cancer Center
NCT06225427
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford University
NCT03582124
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
University of Washington
NCT05570825
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
NCT07017829
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
NCT05501665
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
NCT04780568
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Dwight Owen
NCT06616623
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Emory University
NCT05244239
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
University of Washington
NCT06518057
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
Mayo Clinic
NCT06660407
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Emory University
NCT06731270
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Emory University
NCT05493566
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
City of Hope Medical Center
NCT06249282
Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
Mayo Clinic
NCT05746325
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
NCT05633602
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03793179
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03391869
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer
Ohio State University Comprehensive Cancer Center
NCT05215769
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
M.D. Anderson Cancer Center
NCT03410043
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
NCT02496663
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
NCT04268550
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04310007
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT04625647
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
NCT04533451
Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer
OHSU Knight Cancer Institute
NCT04946279
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT05096663
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
NCT03025256
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 32 |
| Phase 2 | 27 |
| Phase 3 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IV Lung Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IV Lung Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IV Lung Cancer AJCC v8 page
82 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Stage IV Lung Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Stage IV Lung Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IV Lung Cancer AJCC v8 condition card totals 82 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.